Clinigen Share Discussion Threads

[hutch_pod] 20/8/2014 09:32

Excellent news from share price and look forward to GAP and CTS pipeline updates to kick the year off nicely.

[gucci] 20/8/2014 08:46

Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

Clinigen Specialty Pharmaceuticals division expands to five products

Burton-on-Trent, UK - 20 August 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol® (amifostine) from AstraZeneca.

Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.

In 1995, the US Food and Drug Administration (FDA) granted Ethyol a New Drug Application ('NDA') and in 2013, Ethyol revenue was approximately $4.9million.

This is the second product Clinigen has acquired from AstraZeneca (the first being the anti-viral Foscavir® in 2010), and the Group's third oncology support product adding to Cardioxane® and Savene® bringing the Specialty Pharmaceuticals portfolio to five products in total.

Under the terms of the agreement, Clinigen will assume full responsibility for the distribution of the product with immediate effect. AstraZeneca, working closely with Clinigen, will continue to manufacture the product whilst the NDA and Investigational New Drug ('IND') authorizations are transferred and the technical transfer to a third party manufacturer is completed. The acquisition will be paid for in milestone related stage payments linked to the transfer of manufacturing. The financial terms of the agreement are not disclosed.

Peter George, Chief Executive Officer, Clinigen Group, said: "I am very pleased to be working with the AstraZeneca team again. In acquiring Ethyol, as well as bringing our total number of products to five, we now have a portfolio of three oncology support products, adding to Cardioxane® and Savene®. This acquisition is in line with our stated strategy of acquiring niche, hospital-only therapies which have the potential to save and improve the lives of critically ill patients. Ethyol was originally identified through our acquisition database of large pharma product candidates as a very good fit for Clinigen's business model; whilst it was one of the original 12 targets and took some time to close, it is further evidence that the Clinigen model works."

- Ends -

[essential] 19/8/2014 10:52

Needs to be a close over 400p!

[hutch_pod] 19/8/2014 10:37

Tiptoeing over 400

[hutch_pod] 18/8/2014 18:45

My volume charts seem messed up, but 400k traded by close is pretty decent for CLIN i think. Averages are massively skewed by the founder part selling.

[essential] 18/8/2014 12:12

Needs to break 400p and then I would be interested in getting involved again. You have to be careful after a Sunday paper tip in August with low volumes!!

[dasv] 18/8/2014 10:58

A higher high would be nice. On current resistance at the moment.

[hutch_pod] 18/8/2014 10:46

Looks like a fair chance to break 400

[nw99] 18/8/2014 08:04

Good daily mail tip like the story have bought here

[hutch_pod] 17/8/2014 15:01

Would be rude not to?

[cestnous] 17/8/2014 12:38

Well spotted Jane. Whoosh Monday?

[jane downs] 17/8/2014 07:20

MIDAS SHARE TIPS: Drugs firm Clinigen comes off boil but has right chemistry to be a winner - CLIN, MIDAS SHARES TIPS
- Today, 7:20 AM

[hutch_pod] 28/7/2014 15:51

And the Leavers have indeed sold 5.6m shares, and transferred 2.6m to Mr Leaver's mum. Lucky mum.

[hutch_pod] 28/7/2014 10:10

So Grandeur Peak Global Advisors topped up to 4.3m shares.

[hutch_pod] 26/7/2014 14:43

Edison have maintained target at 511-561p.

hxxp://www.-.com/research/trading-update-confirms-investment-case-intact-84974/

Guess an RNS should come this week on the seller

[hutch_pod] 25/7/2014 16:11

oh, i didn't hear. that would explain the endless chunks at 367

[druinsky] 25/7/2014 15:54

founder selling, 15m sold

[dasv] 25/7/2014 15:53

this will hopefully be RNS'd in a holding announcement. pretty fat volume

[hutch_pod] 25/7/2014 15:39

Looks like some monster sells at 367. Huge volumes. Perhaps that was holding the price down?

[nermil] 25/7/2014 15:33

Tough damn crowd. This is not a happy market. This is the second company I've had to launch great results and get flogged for it.

[hutch_pod] 24/7/2014 17:12

hopefully get a steady rise once the sellers finish up

[cestnous] 24/7/2014 11:06

Yes, all looks to be on track. Nice rise this am, despite ADVFN's chart showing no increase